For much of the past decade, patients curious about regenerative approaches such as stem cell and exosome therapy faced an awkward choice. Many of the most discussed protocols were offered only overseas, prompting thousands of Americans each year to board flights to clinics in Mexico, Panama, and Colombia. That pattern, commonly described as medical tourism, is now beginning to shift as more of this care becomes available closer to home.
The change matters for reasons well beyond convenience. When a patient travels abroad for a procedure, continuity of care can suffer. Follow-up visits become difficult, medical records may not transfer cleanly between providers, and recourse is limited if questions surface later. Public-health researchers have long flagged these gaps as a genuine concern for anyone weighing investigational procedures far from home, especially when complications may not appear until weeks after a patient has returned.
Domestic access does not remove the need for caution. In the United States, regenerative therapies remain investigational for most conditions, and the field is still working through the experimental stages that separate early promise from settled science. What domestic access does provide is oversight: care delivered in an FDA registered lab environment, records that stay within reach, and a physician a patient can return to when they have questions.
According to published research summarized by the National Institutes of Health, cell-based and exosome approaches are an active area of study, with outcomes that continue to be evaluated. That framing is important. Regenerative medicine is not a guaranteed outcome or a substitute for conventional care; it is a developing set of protocols that may help support the body’s own repair processes for some patients, with results that may vary from person to person.
Clinicians who work in the space say the domestic shift is overdue. “Patients should not have to leave the country to have an informed conversation about regenerative options,” notes Dr. Charles Pereyra, MD of Springs Rejuvenation, a physician who works with stem cell and exosome protocols. “When care happens here, we can document everything, follow patients over time, and be honest about what the evidence does and does not show.”
That candor is part of what patient advocates would like to see more of. The regenerative field has attracted its share of overstated marketing, and the distance involved in medical tourism can make it harder for patients to separate credible providers from opportunistic ones. Keeping care domestic makes verification easier: patients can check credentials, tour a facility, and ask how a protocol is handled before committing. Independent verification, advocates argue, is one of the strongest protections a patient has.
What Patients Should Ask
Experts encourage anyone considering regenerative therapy to treat it like any other significant medical decision. A few questions consistently separate a thoughtful provider from a promotional one, and patients should feel free to ask every one of them.
Is the lab environment properly registered, and how are biologic materials handled? Sourcing and processing standards vary widely, and patients deserve clear answers before moving forward with any protocol.
What does the current evidence actually support? A trustworthy clinician will describe protocols as experimental where appropriate rather than promising a cure or a guaranteed result.
What does follow-up look like? Ongoing care is where domestic providers hold a real advantage over distant clinics that a patient may never visit again.
The broader takeaway is not that overseas care is uniformly poor or that domestic care is automatically superior. It is that access and accountability tend to travel together. As more physicians offer regenerative protocols within the United States, patients gain the ability to make decisions with fuller information and closer support throughout the process.
For a field still defining itself, that shift toward transparency may prove as significant as any single protocol. Patients weighing stem cell or exosome therapy are best served by asking hard questions, seeking providers who welcome them, and remembering that these approaches remain investigational. Regenerative therapy may help support recovery for some individuals, but it is not FDA approved for most uses, and outcomes are not guaranteed.
This article is for general information only and does not constitute medical advice. Regenerative therapies discussed here are not FDA approved for most conditions and remain in experimental stages; results may vary.
